<DOC>
	<DOCNO>NCT00514969</DOCNO>
	<brief_summary>This phase II , multi-center , open-label , non-randomized trial . During Part 1 trial , patient receive daily oral administration STI571 dose 600 mg 24 week . After complete 24 week therapy , patient may eligible receive additional therapy Part 2 trial provide , opinion investigator , patient benefit treatment STI571 absence safety concern . During Part 2 ( indefinite duration ) , patient continue receive STI571 daily basis either death , development intolerable toxicity investigator feel longer patient 's best interest continue therapy , whichever come first .</brief_summary>
	<brief_title>Protein-Tyrosine Kinase Inhibitor ( STI571 ) Treatment Patients With Ph+ Chronic Myeloid Leukemia Accelerated Blastic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Male female patient * 18 year age 2 . Accelerated phase CML define presence one following : percentage blast blood bone marrow * 15 % &lt; 30 % percentage blast plus promyelocytes peripheral blood bone marrow * 30 % ( provide &lt; 30 % blast present bone marrow ) peripheral basophil * 20 % thrombocytopenia &lt; 100 x 109/L unrelated therapy These criterion must meet within 4 week administration first dose trial treatment . 3 . Blastic phase CML define presence one following : percentage blast blood bone marrow * 30 % percentage blast promyelocytes blood bone marrow * 50 % documented extramedullary blast involvement ( skin , lymph node , bone , lung ) . 4 . Voluntary write informed consent . 1 . Patients childbearing potential wihout negative pregnancy test prior initiation study drug . Barrier contraceptive precaution use throughout trial sex . 2 . Patients ECOG Performance Status Score ** 3 ( see Section 7.2.1 ) 3 . Creatinine level 2 x 's ULN laboratory analysis perform . 4 . Total serum bilirubin 1.5 x 's upper limit normal range ( ULN ) laboratory analysis perform ; patient clinically suspect leukemic involvement liver , total bilirubin 3 x 's ULN 5 . AST ( SGOT ) ALT ( SGPT ) 3 x 's upper limit normal range ( ULN ) laboratory analysis perform ; patient clinically suspect leukemic involvement liver , AST ALT 5 x 's ULN 6 . Patients receive treatment interferonalpha within 48 hour Day 1 . 7 . Patients receive treatment hydroxyurea within 24 hour Day 1 8 . Patients receive treatment homoharringtonine within 14 day Day 1 9 . Patients receive treatment lowdose cytosine arabinoside ( &lt; 30 mg/m2 every 12 24 hour administer daily ) within seven day Day 1 10 . Patients receive treatment moderate dose cytosine arabinoside ( 100200 mg/m2 5 6 day ) within 14 day Day 1 . 11 . Patients receive treatment highdose cytosine arabinoside ( 13 g ( m2 every 12 24 hour six 12 dos ) within 28 day Day 1 . 12 . Patients receive anthracyclines , mitoxantrone , etoposide , methotrexate cyclophosphamide within 21 day Day1 . 13 . Patients receive busulfan within six week Day 1 . 14 . Patients receive antileukemic agent include Exclusion Criteria 613 begin treatment STI571 sufficient time elapse potential recovery occur nadir blood count . In practice , full recovery blood count may possible due progression underlie disease . 15 . Patients receive hematopoietic stem cell transplantation achieve full hematopoietic recovery follow transplant 16 . Patients receive investigational agent within 28 day Day 1 . 17 . Patients Grade Â¾ cardiac disease . 18 . Patients serious concomitant medical condition 19 . Patients history noncompliance medical regimen consider potentially unreliable . 20 . Patients prior diagnosis accelerate blastic phase remission fit inclusion criterion , eligible . 21 . Patients likely submitted procedure stem cell transplantation end treatment ( 6 month ) , eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>accelerate blastic phase</keyword>
	<keyword>STI571</keyword>
</DOC>